Mechanism of absorbable bioglass injection for vertebral body supporting and osteogenic induction in osteoporosis

doi:10.3969/j.issn.2095-4344.2016.12.003

Abstract

Abstract:

BACKGROUND: Bioglass has good biocompatibility and biological activity, which can be combined with calcium phosphate bone cement to form an absorbable bioglass that has the advantages of both materials and is expected to have a better use of space.
OBJECTIVE: To explore the mechamism of the new type of absorbable bioglass injection for vertebral body supporting and osteogenic induction in osteoporosis rats.
METHODS: Twenty-seven female Sprague-Dawley rats were selected to make osteoporosis models by bilateral ovariectomy, and after 1 month, the rats were randomized into three groups. Bone defect models were established in the lumbar L4 segment of all the rats. Rats in the experimental group were subjected to absorbable bioglass injection; rats in the control group 1 underwent polymethylmethacrylate bone cement injection; and rats in the control group 2 were given injectable calcium phosphate. Twelve weeks after implantation, the compressive strength, degradation and osteogenesis of the implant materials were detected, and levels of serum bone morphogenetic protein-2 and transforming growth factor-β were measured.
RESULTS AND CONCLUSION: The compressive strength, hydroxyapatite deposition amount, and weight loss ratio in the experimental group were significantly higher than those in the two control groups (P < 0.05); the relative volume, thickness and number of bone trabeculae in the experimental group were significantly higher than those in the control groups (P < 0.05); the bone morphogenetic protein-2 and transforming growth factor-β protein levels in the experimental group were significantly higher than those in the two control groups (P < 0.05). These findings indicate that the new-type absorbable bioglass can greatly strengthen the vertebral body supporting and promote osteogenic effect in osteoporosis by enhancing the bone morphogenetic protein-2 and transforming growth factor-β protein levels.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Long Hai-bin, Hu Ying-ying, Sun Gui-sen. Mechanism of absorbable bioglass injection for vertebral body supporting and osteogenic induction in osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(12): 1690-1696.

Figures/Tables 3

References

[1] Mithal A,Dhingra V,Lau E.The Asian audit: Epidemiology, costs and burden of osteoporosis in Asia. Beizing, China: An International Osteoporosis Foundation (IOF) publication,2009.

[2] Ward E,Munk PL,Rashid F,et al.Musculoskeletal interventional radiology: radiofrequency ablation. Radiol Clin North Am.2008;46:599-610.

[3] Cummings SR,San Martin J,Mc Clung MR,et al.FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med.2009;361(8):756-765.

[4] Aghaloo T,Felsenfeld A,Tetradis S.Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg.2010;68(5):959-963.

[5] Taylor KH,Middlefell LS,Mizen KD.Osteonecrosis of the jaws induced by anti-RANK ligand therapy.Br J Oral Maxillofac Surg.2010;48(3):221-223.

[6] Xu HHK,Zhao L,Detamore MS,et al.Umbilical cord stem cell seeding on fast-resorbable calcium phosphate bone cement.Tissue Eng A.2010;16: 2743-2753.

[7] 叶冬平,周子强,梁伟国.一种可注射自固化含锶复合胶原磷酸钙骨水泥的结构和性能[J].中国组织工程研究与临床康复,2009,13(38):7411.

[8] Bone HG,McClung MR,Roux C.Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.J Bone Miner Res.2010;25(5):937-947.

[9] Ginebra MP,Canal C,Espanol M,et al.Calcium phosphate cements as drug delivery materials. Adv Drug Del Rev.2012;64:1090-1110.

[10] Lanao RP,Leeuwenburgh SC,Wolke JG,et al. In vitro degradation rate of apatite calcium phosphate cement with incorporated PLGA microspheres. Acta Biomater. 2011;7:3459-3468.

[11] Yuan H,Bruijn JD,Zhang X,et al.Bone induction by porous glass ceramic made from Bioglass(45S5).J Biomed Mater Res.2001;58(3):270-276.

[12] Kirk JF,Ritter G,Waters C,et al.Osteoconductivity and osteoinductivity of NanoFUSE® DBM.Cell Tissue Bank. 2013;14(1):33-44.

[13] Rojbani H,Nyan M,Ohka K,et al.Evaluation of the osteoconductivity of α-tricalcium phosphate, β-tricalcium phosphate, and hydroxyapatite combined with or without simvastatin in rat calvarial defect.J Biomed Mater Res Part A.2011;98:488-498.

[14] Hoppe A,Guldal NS,Boccaccini AR. A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics. Biomaterials. 2011; 32(11):2757-2774.

[15] Gerhardt LC,Widdows KL,Erol MM,et al.The pro-angiogenic properties of multi-functional bioactive glass composite scaffolds.Biomaterials.2011; 32(17): 4096-4108.

[16] Hautamaki M,Meretoja VV,Mattila RH,et al.Osteoblast response to polymethyl methacrylate bioactive glass composite.J Mater Sci Mater Med.2010;21:1685-1692.

[17] Nogueira ML,Lucas R,Ramos I,et al.Osteodensimetric curves in a female population.Acta Reumatol Port. 2011; 36(2):126-136.

[18] Sendtner E,Renkawitz T,Kramny P,et a.l Fractured neck of femur--internal fixation versus arthroplasty. Dtsch Arztebl Int.2010;107(23):401-407.

[19] Katsumura S,Ezura Y,Izu Y,et al.Beta Adrenergic Receptor Stimulation Suppresses Cell Migration in Association with Cell Cycle Transition in Osteoblasts-Live Imaging Analyses Based on FUCCI System.J Cell Physiol. 2016;231(2):496-504.

[20] Buckens CF,van der Graaf Y,Verkooijen HM,et al. Osteoporosis markers on low-dose lung cancer screening chest computed tomography scans predict all-cause mortality. Eur Radiol.2015;25(1):132-139.

[21] Leite AF,Souza Figueiredo PT,Caracas H,et al. Systematic review with hierarchical clustering analysis for the fractal dimension in assessment of skeletal bone mineral density using dental radiographs.Oral Radiol.2015;31(1):1-13.

[22] Liu YQ,Han XF,Liu T,et al. A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis.Biotechnol Lett.2015; 37(1): 219-226.

[23] Gosch M,Druml T,Nicholas JA,et al.Fragility non-hip fracture patients are at risk.Arch Orthop Trauma Surg. 2015;135(1):69-77.

[24] Kim HJ,Park TJ,Ahn KM.Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases.Maxillofac Plast Reconstr Surg.2016;38(1):6.

[25] Ballas EG,Mavrogenis AF,Karamanis E,et al.Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.Eur J Orthop Surg Traumatol.2015;25(1):181-187.

[26] Schröder K.NADPH oxidases in bone homeostasis and osteoporosis.Cell Mol Life Sci.2015;72(1):25-38.

[27] Sale JE,Hawker G,Cameron C,et al.Perceived messages about bone health after a fracture are not consistent across healthcare providers.Rheumatol Int. 2015;35(1):97-103.

[28] Zhang H,Tao X,Wu J.Association of calcitonin receptor gene polymorphism with bone mineral density in postmenopausal Chinese women: a meta-analysis. Arch Gynecol Obstet.2015;291(1):165-172.

[29] Reid IR.Effects of vitamin D supplements on bone density.J Endocrinol Invest. 2015;38(1):91-94.

[30] Ishtiaq S,Fogelman I,Hampson G.Treatment of post-menopausal osteoporosis: beyond bisphosphonates.J Endocrinol Invest.2015;38(1): 13-29.

[31] Isidori AM,Balercia G,Calogero AE,et al.Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.J Endocrinol Invest.2015; 38(1):103-112.

[32] Makita K,Okano H,Furuya T,et al.Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan.J Bone Miner Metab.2015;33(1): 55-60.

[33] Horst-Sikorska W,Dytfeld J,Wawrzyniak A,et al.Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis.Mol Biol Rep.2013;40(1):383-390.

[34] Peppone LJ,Mustian KM,Rosier RN,et al.Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study.Support Care Cancer. 2014;22(1):245-251.

[35] Venmans A,Lohle PN,van Rooij WJ.Pain course in conservatively treated patients with back pain and a VCF on the spine radiograph (VERTOS III).Skeletal Radiol. 2014;43(1):13-18.

[36] Mikami Y,Matsumoto T,Kano K,et al.Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine. Anat Sci Int.2014;89(1):1-10.

[37] Iino M, Kozai Y,Kawamata R,et al. Effects of β-cryptoxanthin on bone-formation parameters in the distal femoral epiphysis of ovariectomized mice.Oral Radiol.2014;30(1):1-8.

[38] Miura T,Kozai Y,Kawamata R,et al.Inhibitory effect of a fermented soy product from lactic acid bacteria (PS-B1) on deterioration of bone mass and quality in ovariectomized mice.Oral Radiol.2014;30(1):45-52.

[39] Berendsen AD,Olsen BR.Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology.Cell Mol Life Sci.2014;71(3):493-497.

[40] Roux C,Binkley N,Boonen S,et al.Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.Calcif Tissue Int.2014;94(2):153-157.

[41] Jeon YK,Kim KM,Kim KJ, et al.The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol.Calcif Tissue Int. 2014;94(2): 159-168.

[42] He Q,Chen H,Huang L,et al.Porous surface modified bioactive bone cement for enhanced bone bonding. PLoS One.2012;7:e42525.